Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPMPA (NMDA antagonist)
Description: Competitive NMDA antagonist
Alternative Names: PMPC
Chemical Name: 4-(Phosphonomethyl)-2-piperazinecarboxylic acid
Biological Activity for PMPA (NMDA antagonist)
PMPA (NMDA antagonist) is a competitive NMDA receptor antagonist. Displays Ki values of 0.84, 2.74, 3.53 and 4.16 μM at GluN2A, GluN2B, GluN2C and GluN2D subunit-containing receptors respectively. Selective over AMPA receptors.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Technical Data for PMPA (NMDA antagonist)
| M. Wt | 224.15 |
| Formula | C6H13N2O5P |
| Storage | Store at +4°C |
| CAS Number | 113919-36-1 |
| PubChem ID | 17756792 |
| InChI Key | ILRBBHJXTYIHTP-UHFFFAOYSA-N |
| Smiles | OP(CN1CC(C(O)=O)NCC1)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for PMPA (NMDA antagonist)
References for PMPA (NMDA antagonist)
References are publications that support the biological activity of the product.
Harris and Davies (1992) Cortically evoked excitatory synaptic transmission in the cat red nucleus is antagonised by D-AP5 but not by D-AP7. Brain Res. 594 176 PMID: 1361408
Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354 PMID: 15721167
View Related Products by Target
View Related Products by Product Action
Keywords: PMPA (NMDA antagonist), PMPA (NMDA antagonist) supplier, Competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, PMPC, 2273, Tocris Bioscience
Citations for PMPA (NMDA antagonist)
Citations are publications that use Tocris products.
Currently there are no citations for PMPA (NMDA antagonist).
Reviews for PMPA (NMDA antagonist)
Average Rating: 5 (Based on 1 Review.)
Have you used PMPA (NMDA antagonist)?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Antagonism at NMDA receptor.
By
Sergiy Sylantyev on 11/29/2020
Species: Human
PMPA was in use as an NMDA receptor antagonist affecting glutamate site, to study (possible) competition of dopamine for this site. Application of PMPA and dopamine mixtures in different ratios resulted in a decrease of single-channel NMDA receptor openings recorded from outside-out neuron membrane patches. No problem with dissolution in water up to 10 mM concentration.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.